• Publications
  • Influence
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
To facilitate clinical trials of disease-modifying therapies for Alzheimer’s disease, which are expected to be most efficacious at the earliest and mildest stages of the disease, supportive biomarkerExpand
  • 472
  • 15
  • PDF
Novel plasma biomarker surrogating cerebral amyloid deposition
Alzheimer’s disease (AD) is the most common and devastating dementia. Simple and practical biomarkers for AD are urgently required for accurate diagnosis and to facilitate the development ofExpand
  • 75
  • 2
Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
Proteolytic processing of the amyloid precursor protein (APP) by β-secretase and γ-secretase leads to the generation and deposition of amyloid β (Aβ) in Alzheimer’s disease (AD). N-terminally orExpand
  • 36
  • 2
Flexible antibodies with nonprotein hinges
There is a significant need for antibodies that can bind targets with greater affinity. Here we describe a novel strategy employing chemical semisynthesis to produce symmetroadhesins: antibody-likeExpand
  • 7
Multi epitope-targeting immunoprecipitation using F(ab') fragments with high affinity and specificity for the enhanced detection of a peptide with matrix-assisted laser desorption
Human plasma has been frequently studied using mass spectrometry for new biomarker discovery, although detection of low-abundance biological molecules can be challenging due to sample complexity andExpand
  • 8
PLASMA BIOMARKER WITH HIGH ACCURACY IN PREDICTING BRAIN AMYLOID-β BURDEN: INITIAL RESULTS ACROSS TWO INDEPENDENT LARGE COHORTS—NCGG (JAPAN) AND AIBL (AUSTRALIA)
dementia, delirium with dementia or delirium alone. Methods: A systematic review and meta-analysis was undertaken using a predefined search strategy. Titles and abstracts of studies were screened toExpand
Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease.
BACKGROUND Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationshipExpand
...
1
2
...